<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384692</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006507</org_study_id>
    <secondary_id>NCI-2020-01626</secondary_id>
    <secondary_id>10093</secondary_id>
    <nct_id>NCT04384692</nct_id>
  </id_info>
  <brief_title>Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis</brief_title>
  <official_title>Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well administering ruxolitinib before, during, and after&#xD;
      allogeneic hematopoietic stem cell transplantation works in preventing graft versus host&#xD;
      disease and improving transplant outcomes in patients with primary and secondary&#xD;
      myelofibrosis. Donor hematopoietic stem cell transplantation (HSCT) is currently the only&#xD;
      treatment with proven curative potential for myelofibrosis, however, myelofibrosis patients&#xD;
      have a high risk for developing graft versus host disease post-transplant. Graft versus host&#xD;
      disease is a condition where the transplanted cells from a donor can attack the body's normal&#xD;
      cells. Ruxolitinib, a janus-associated kinase (JAK) inhibitor, is known to decrease&#xD;
      inflammatory signals, which may reduce spleen size and decrease symptoms such as night sweats&#xD;
      and weight loss. Administering ruxolitinib before, during, and after transplant may decrease&#xD;
      the incidence and severity of graft versus host disease, increase survival, and improve&#xD;
      quality of life in patients with primary and secondary myelofibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      PART 1: Patients receive ruxolitinib orally (PO) starting 8 weeks prior to hematopoietic stem&#xD;
      cell transplantation (HSCT) and continuing until approximately 14 days prior to conditioning&#xD;
      regimen, then tapered per the treating clinician until day -4 in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients who join a different research study for Part 2&#xD;
      have their collected data and samples from Part 1 carried over to the new protocol.&#xD;
&#xD;
      PART 2: Patients are assigned to either a high (myeloablative) or reduced intensity&#xD;
      conditioning regimens per the clinical provider together with the Clinical Coordinators&#xD;
      Office (CCO):&#xD;
&#xD;
      MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide intravenously (IV) on days -7&#xD;
      and -6 and busulfan IV over 3 hours on days -5 to -2. Patients with umbilical cord blood&#xD;
      (UCB) as their transplant source also receive fludarabine IV over 30 minutes on days -8 to&#xD;
      -6. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      REDUCED INTENSITY CONDITIONING: Patients receive fludarabine IV over 30 minutes on days -6 to&#xD;
      -2 and melphalan IV over 15-30 minutes on days -3 and -2. Patients with UCB as their&#xD;
      transplant source also undergo total body irradiation (TBI) on day -1. Treatment continues in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      TRANSPLANT: After completion of conditioning regimen, patients undergo HSCT on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Patients receive ruxolitinib until approximately 7 months post-transplant&#xD;
      and then tapered over 2 months until 9 months post HSCT. Patients also receive tacrolimus IV&#xD;
      continuously (inpatients) or every 12 hours (outpatients) beginning day -1 (day -3 for&#xD;
      patients with UCB as their donor source), then PO twice daily (BID) once therapeutic levels&#xD;
      are reached, with a taper beginning on day 56 for patients with related donors, and day 100&#xD;
      for patients with unrelated donors over 4 months in the absence of GVHD. The duration of&#xD;
      tacrolimus for patients with GVHD is determined by the attending physician. Patients with&#xD;
      related and unrelated donors also receive methotrexate IV on days 1, 3, 6, and 11. Patients&#xD;
      with UCB as their transplant source also receive mycophenolate mofetil IV or PO every 8 hours&#xD;
      beginning on days 0-30, then tapered until day 40 in the absence of GVHD. All treatment&#xD;
      continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed up at 6 months, 1 year, and 2-5 years after completion of HSCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade II-IV graft versus host disease (GVHD) in myelofibrosis patients</measure>
    <time_frame>Up to day 100</time_frame>
    <description>The probability of grade II-IV acute GVHD observed in this study will be compared to a fixed benchmark, this fixed benchmark derived from the results of a previous study (FH Protocol 9033).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade III-IV GVHD</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Estimated as simple proportions and informally compared to the results from FH Protocol 9033.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>Up 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate (OS)</measure>
    <time_frame>At 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary and secondary graft failure</measure>
    <time_frame>6 months</time_frame>
    <description>Estimated as simple proportions and informally compared to the results from FH Protocol 9033.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil (ANC &gt; 500) engraftment</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet (&gt; 20,000) engraftment</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>Day 100 and 1 year</time_frame>
    <description>Estimated as simple proportions and informally compared to the results from FH Protocol 9033.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <condition>Secondary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo HSCT</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplantation, Allogeneic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>INCB-18424</other_name>
    <other_name>INCB18424</other_name>
    <other_name>Jakafi</other_name>
    <other_name>Oral JAK Inhibitor INCB18424</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
    <other_name>Total-Body Irradiation Prior to Stem Cell Transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  JAK INHIBITOR ADMINISTRATION INCLUSION: (PART I)&#xD;
&#xD;
          -  Disease criteria:&#xD;
&#xD;
               -  Diagnosis of primary myelofibrosis (PMF) as defined by the 2016 World Health&#xD;
                  Organization classification system or diagnosis of secondary myelofibrosis (MF)&#xD;
                  as defined by the International Working Group (IWG) for Myeloproliferative&#xD;
                  Neoplasms Research and Treatment criteria&#xD;
&#xD;
               -  Patients meeting the criteria for intermediate-1, intermediate-2 or high-risk&#xD;
                  disease by Dynamic International Prognostic Scoring System (DIPSS) or DIPSS plus&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Patient must be a potential hematopoietic stem cell transplant candidate as assessed&#xD;
             by the consenting physician&#xD;
&#xD;
          -  Patient must be willing to start ruxolitinib within a 6-month time period&#xD;
&#xD;
          -  ALLOGENEIC STEM CELL TRANSPLANT INCLUSION: (PART II)&#xD;
&#xD;
          -  Meeting criteria for part 1, as above, at time of initiation of ruxolitinib, including&#xD;
             the ability to understand and willingness to sign a written informed consent. Patients&#xD;
             arriving to our institution for transplant and not enrolled in part 1 may still be&#xD;
             enrolled in part 2 if part 1 criteria are met. These patients will have part 1&#xD;
             endpoints transcribed from medical records&#xD;
&#xD;
          -  Received ruxolitinib for at least 8 weeks immediately prior to conditioning and be&#xD;
             willing to continue until 9 months post-transplant as tolerated&#xD;
&#xD;
          -  Performance status score: Karnofsky &gt;= 70&#xD;
&#xD;
          -  Calculated creatinine clearance using the Cockcroft-Gault formula or 24 hour (hr)&#xD;
             urine creatinine clearance must be &gt; 60 ml/min&#xD;
&#xD;
          -  Total serum bilirubin must be &lt; 3 mg/dL unless the elevation is thought to be due to&#xD;
             Gilbert's disease or hemolysis&#xD;
&#xD;
          -  Transaminases must be &lt; 3 x the upper limit of normal&#xD;
&#xD;
          -  Patients with clinical or laboratory evidence of liver disease will be evaluated for&#xD;
             the cause of liver disease, its clinical severity in terms of liver function, and the&#xD;
             degree of portal hypertension. Patients with fulminant liver failure, cirrhosis with&#xD;
             evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, hepatic&#xD;
             encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation&#xD;
             of the prothrombin time, ascites related to portal hypertension, bacterial or fungal&#xD;
             abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin &gt;&#xD;
             3mg/dL, and symptomatic biliary disease will be excluded&#xD;
&#xD;
          -  Diffusion capacity of lung for carbon monoxide (DLCO) corrected &gt; 60% normal. May be&#xD;
             not be on supplemental oxygen&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt; 40% OR shortening fraction &gt; 26%&#xD;
&#xD;
          -  Comorbidity index &lt; 5 at the time of pre-transplant evaluation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  JAK INHIBITOR ADMINISTRATION EXCLUSION: (PART I)&#xD;
&#xD;
          -  Contraindication to receiving ruxolitinib including:&#xD;
&#xD;
               -  Patients who have known hypersensitivity to JAK inhibitors&#xD;
&#xD;
               -  Clinical or laboratory evidence of significant renal or hepatic impairment&#xD;
                  including cirrhosis&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
               -  Known human immunodeficiency virus (HIV) positivity&#xD;
&#xD;
               -  Women who are pregnant or trying to conceive&#xD;
&#xD;
               -  Caution should be used in patients with platelets &lt; 100 though adjustments in&#xD;
                  dose can be made to accommodate anyone with platelets &gt; 50&#xD;
&#xD;
          -  History of prior allogeneic transplant&#xD;
&#xD;
          -  Leukemic transformation (&gt; 20% blasts)&#xD;
&#xD;
          -  ALLOGENEIC STEM CELL TRANSPLANT EXCLUSION: (PART II)&#xD;
&#xD;
          -  Uncontrolled viral or bacterial infection at the time of transplant data review and&#xD;
             consent conference&#xD;
&#xD;
          -  Active or recent (prior 6 month) invasive fungal infection without infectious disease&#xD;
             (ID) consult and approval&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Patients without a human leukocyte antigen (HLA)-identical sibling donor, 10 of 10&#xD;
             HLA-matched or 9 of 10 allele mismatched unrelated donor, or umbilical cord blood&#xD;
             units that meet transplant criteria&#xD;
&#xD;
          -  Patients with a spleen &gt; 22 cm (&gt;16 cm for cord blood patients) who have NOT received&#xD;
             a surgical splenectomy consultation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel B. Salit</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel B. Salit</last_name>
    <phone>206.667.1317</phone>
    <email>rsalit@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel B. Salit</last_name>
      <phone>206-667-1317</phone>
      <email>rsalit@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Rachel B. Salit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

